About — Operon Research

Independent research, built around the data that actually moves this industry.

Operon Research is an independent publisher covering Life Science Tools, Diagnostics, and the broader life sciences value chain. We exist to give institutional decision-makers a clearer read on the industry — informed by proprietary trackers, written by people who've spent careers in the sector, and unconstrained by the conflicts that shape sell-side coverage.

The work behind Operon

Founder & Senior Analyst

Jack Meehan, CFA

Jack is the founder of Operon Research and leads coverage of Life Science Tools, Diagnostics, the Labs, and CROs. He has spent over fifteen years analyzing this industry on the sell-side — most recently as Partner and Senior Analyst at Nephron Research, and previously at Barclays — with a track record of non-consensus calls and institutional-grade modeling.

Operon was founded to bring that work directly to institutional readers — free of the conflicts and constraints of traditional sell-side research, and focused on what drives industry growth and competitive share shift rather than buy-sell-hold ratings.

Jack holds the Chartered Financial Analyst (CFA) designation. He is based in New Jersey.

Jesse Coulter

Jesse is an Associate on Operon's Life Science Tools and Diagnostics team. He holds a B.S. in Mechanical Engineering and a B.S. in Integrated Business and Engineering with a concentration in Finance from Lehigh University — a dual-degree program designed for students working at the intersection of technical and financial analysis. Before joining Operon, he gained experience across healthcare consulting, corporate finance, and data analytics. He is originally from Allentown, Pennsylvania.

How we work

Data first. Then the analysis.

Operon's research is built on a stack of proprietary trackers and datasets that we maintain continuously and refresh against every relevant data release. Each report and model is grounded in this data layer before any narrative is written.

The data layer.

Operon tracks NIH funding flows and outlays via Reporter, clinical trials activity, life sciences hiring through job postings data, web traffic patterns for the companies we cover, and other public and licensed data sources. Each tracker is designed to read against a specific question: where the dollars are flowing, where research activity is accelerating, where companies are investing in capacity, and how end-market demand is shifting in real time.

The analytical layer.

Operon's research applies decades of combined experience covering the sector to translate the data into industry read-throughs: company earnings previews and reviews, benchmarking analyses across the value chain, thematic deep dives, and our weekly Signal report.

The output.

Subscribers receive published research on a regular cadence, supported by financial models that are updated as new data lands. Operon does not issue ratings or price targets. Our focus is on what drives industry growth and competitive share shift.

Research without the conflicts.

Traditional sell-side research operates inside institutions that are also banking, trading, and lending counterparties to the companies being covered. Those conflicts shape what gets published, when, and how directly. They are managed — not eliminated.

Operon was built outside that structure. We are an independent financial publisher operating under the publisher's exemption to the Investment Advisers Act of 1940. We do not bank, trade, or hold positions in the companies we cover, and we do not issue investment ratings or price targets.

What that means in practice: our incentives line up with the quality of our analysis and the durability of our subscriber relationships, not with banking mandates or trading flows. Subscribers get a clearer, more direct read on the industry — written for them, not around them.